Edgewise Therapeutics (EWTX) Stock Forecast & Price Target $32.72 -0.10 (-0.29%) As of 02:49 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Edgewise Therapeutics - Analysts' Recommendations and Stock Price Forecast (2026) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating Moderate BuyBased on 9 Analyst RatingsSell1Hold1Buy7 Based on 9 Wall Street analysts who have issued ratings for Edgewise Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 9 analysts, 1 has given a sell rating, 1 has given a hold rating, 5 have given a buy rating, and 2 have given a strong buy rating for EWTX. Consensus Price Target $39.6721.22% Upside According to the 9 analysts' twelve-month price targets for Edgewise Therapeutics, the average price target is $39.67. The highest price target for EWTX is $52.00, while the lowest price target for EWTX is $20.00. The average price target represents a forecasted upside of 21.22% from the current price of $32.72. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for EWTX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Edgewise Therapeutics and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EWTX Analyst Ratings Over TimeTypeCurrent Forecast5/21/25 to 5/21/261 Month Ago4/21/25 to 4/21/263 Months Ago2/20/25 to 2/20/261 Year Ago5/21/24 to 5/21/25Strong Buy2 Strong Buy rating(s)2 Strong Buy rating(s)1 Strong Buy rating(s)0 Strong Buy rating(s)Buy5 Buy rating(s)6 Buy rating(s)6 Buy rating(s)7 Buy rating(s)Hold1 Hold rating(s)1 Hold rating(s)2 Hold rating(s)2 Hold rating(s)Sell1 Sell rating(s)1 Sell rating(s)1 Sell rating(s)0 Sell rating(s)Consensus Price Target$39.67$38.44$36.67$40.22Forecasted Upside21.22% Upside18.47% Upside25.10% Upside175.68% UpsideConsensus RatingModerate BuyModerate BuyModerate BuyModerate Buy EWTX Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History EWTX Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Edgewise Therapeutics Stock vs. The CompetitionTypeEdgewise TherapeuticsMedical CompaniesBroader MarketConsensus Rating Score 2.89 2.29 2.52Consensus RatingModerate BuyHoldModerate BuyPredicted Upside20.86% Upside1,725.93% Upside16.45% UpsideNews Sentiment RatingNeutral NewsSee Recent EWTX NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails5/6/2026 Truist Financial3 of 5 stars Set Target$52.00+40.14%4/20/2026 Weiss RatingsNot Rated Reiterated RatingSell (D-)3/17/2026 JPMorgan Chase & Co.3 of 5 starsTessa RomeroNot RatedBoost TargetOverweight$34.00 ➝ $45.00+45.41%3/17/2026 WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLaura ChicoSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingOutperform$32.00+7.45%3/10/2026 Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMartin AusterSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingSet Target$46.00+54.67%2/26/2026 EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingCory KasimovSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingOutperform$45.00+51.72%2/26/2026 Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJames CondulisSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingSet Target$25.00-16.39%2/26/2026 HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating UpgradeStrong-Buy2/9/2026 Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Reiterated RatingOverweight11/7/2025 Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLeonid TimashevSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetOutperform$49.00 ➝ $50.00+189.02% Get the Latest News and Ratings for EWTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Edgewise Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 9/25/2025 The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingPaul ChoiSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoverageNeutral$20.00+20.55%4/30/2025 GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDebjit ChattopadhyaySubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoverageBuy$41.00+165.20%4/2/2025 ScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLouis ChenSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeSector Outperform ➝ Sector Perform$50.00 ➝ $14.00-6.80%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 02:49 PM ET. EWTX Forecast - Frequently Asked Questions What is Edgewise Therapeutics' forecast for 2026? According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Edgewise Therapeutics is $39.67, with a high forecast of $52.00 and a low forecast of $20.00. Should I buy or sell Edgewise Therapeutics stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Edgewise Therapeutics in the last year. There is currently 1 sell rating, 1 hold rating, 5 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" EWTX shares. Does Edgewise Therapeutics's stock price have much upside? According to analysts, Edgewise Therapeutics's stock has a predicted upside of 21.22% based on their 12-month stock forecasts. Has Edgewise Therapeutics been upgraded by Wall Street analysts recently? Over the previous 90 days, Edgewise Therapeutics's stock had 1 upgrade by analysts. What analysts cover Edgewise Therapeutics? Edgewise Therapeutics has been rated by research analysts at Evercore, HC Wainwright, JPMorgan Chase & Co., Raymond James Financial, Stifel Nicolaus, Truist Financial, Wedbush, and Weiss Ratings in the past 90 days. Do Wall Street analysts like Edgewise Therapeutics more than its competitors? Analysts like Edgewise Therapeutics more than other "medical" companies. The consensus rating for Edgewise Therapeutics is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how EWTX compares to other companies. Stock Forecasts and Research Tools Related Companies Regencell Bioscience Stock Forecast BridgeBio Pharma Stock Forecast Axsome Therapeutics Stock Forecast Arrowhead Pharmaceuticals Stock Forecast Elanco Animal Health Stock Forecast Dr. Reddy's Laboratories Stock Forecast Abivax Stock Forecast Praxis Precision Medicines Stock Forecast Cytokinetics Stock Forecast Krystal Biotech Stock Forecast Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Brokerages With Edgewise Therapeutics RecommendationsTruist FinancialWeiss RatingsJPMorgan Chase & Co.WedbushRaymond James FinancialWall Street ZenHC WainwrightEvercoreStifel NicolausPiper SandlerRoyal Bank Of CanadaThe Goldman Sachs Group This page (NASDAQ:EWTX) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edgewise Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edgewise Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
